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ABSTRACT  
 
Metastases are frequently found at colorectal cancer diagnosis and are the main determinants of 
clinical outcome. The lack of reliable models of metastases has precluded their mechanistic 
understanding and our capacity to improve outcome. We studied the effect of E-cadherin and 
Snail1 expression on metastagenesis in a colorectal cancer model. We microinjected SW480-
ADH human colorectal cancer cells transfected with an empty vector (Mock), or 
overexpressing Snail1 (Snail1OE) or E-cadherin (E-cadherinOE) in the cecum of nude mice 
(eight per group) and analyzed tumor growth, dissemination, and Snail1, E-cadherin, β-catenin 
and Presenilin1 (PS1) expression in local tumors and/or metastatic foci. Snail1OE cells 
disseminated only to lymph nodes, whereas Mock or E-cadherinOE cells spread to lymph nodes 
and peritoneum. Peritoneal tumor foci developed by E-cadherinOE cells presented an increase 
in E-cadherin proteolysis and nuclear translocation, and enhanced expression of proteolytically 
active PS1. This was linked to increased tumor growth and shortened mouse survival. 
Interestingly, local and lymph node tumors in mice bearing E-cadherinOE cells overexpressed 
E-cadherin but they did not show E-cadherin proteolysis or nuclear translocation. Remarkably, 
E-cadherin nuclear translocation and enhanced expression of active PS1 were found in a 
patient with colorectal signet-ring cell carcinoma. In conclusion, we have established a 
colorectal cancer metastasis model in which E-cadherin proteolyis and nuclear translocation 
associates with aggressive foci growth only in the peritoneal microenvironment. 
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INTRODUCTION 
 
Metastases are frequently found at colorectal cancer diagnosis and are the main determinants of 
clinical outcome.1 Despite an initial response to therapy they are frequently fatal.2 A 
mechanistic understanding of metastatic dissemination may improve prognosis and outcome. 
 
E-cadherin is a tumor suppressor that maintains epithelial integrity and inhibits migration and 
invasion.3 Its forced expression suppresses tumorigenesis, whereas E-cadherin loss associates 
with adenoma to carcinoma transition in experimental models.4 Transcriptional repression or 
mutational inactivation occurs in diffuse type gastric carcinomas,5 whereas increased 
membranous expression associates with longer cancer patient survival in bladder cancer.6 In 
sporadic colorectal cancer, E-cadherin downregulation has been reported to associate with 
dedifferentiation, progression and metastasis,7 whereas its membranous expression could 
confer good prognosis.8  Intriguingly, E-cadherin is expressed in a subset of metastatic lesions 
in colorectal cancer.9,10 The transcription factor Snail1 represses E-cadherin expression and 
associates with dedifferentiation and invasiveness,11 proliferative block, and increased 
resistance to cell death.12 Snail1 expression correlates with metastasis and poor outcome in 
breast and other cancers,13-15 but this association had not been reported in colorectal cancer.16,17 
A recent study has shown the expression of Snail1 protein in the stroma of colon tumors. 
Interestingly, the presence of Snail1 in this compartment associates with the existence of 
distant metastasis and with shorter patient survival.18 E-cadherin and Snail1 expression have 
been extensively studied in colorectal primary tumors, but they have been less frequently 
evaluated in metastatic foci. 
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The lack of reliable models of metastasis in colorectal cancer has precluded the study of its 
mechanistic basis. We have developed a procedure for the orthotopic microinjection (OCMI) 
of human colon cancer cells in the colonic wall of nude mice to generate a model that 
replicates the relevant metastatic sites observed in human colorectal cancer.19 This model 
allows ex vivo manipulation of cancer cells to study the role of oncogenes or tumor suppressor 
genes in oncogenesis, as we described in a previous report evaluating Rac1.20 
 
Here, we used human colorectal cancer SW480-ADH cells, which express low levels of Snail1 
and E-cadherin,21,22 to derive clones expressing an empty vector (Mock cells), overexpressing 
Snail1 (Snail1OE cells) or overexpressing E-cadherin (E-cadherinOE cells). We studied local 
tumor growth and metastatic dissemination after their orthotopic implantation. We also 
evaluated β-catenin and E-cadherin expression in tumors, since most colorectal cancer cells, 
including SW480-ADH,23 have an active canonical Wnt/β-catenin signaling pathway. This 
leads to β-catenin accumulation within the nucleus, a process inhibited by the interaction of E-
cadherin and β-catenin at the plasma membrane adherens junctions.3 In addition, we assessed 
Presenilin1 (PS1) expression, as this protein regulates E-cadherin cleavage and β-catenin 
transcriptional activity.24 
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METHODS 
 
Generation of stable cell lines 
 
SW480-ADH cells were retrovirally transduced with pRV-IRES-GFP (empty vector) or pRV-
Snail1-IRES-GFP vectors to generate Mock cells or Snail1 overexpressing (Snail1OE) cells, 
respectively.22 E-cadherin overexpressing (E-cadherinOE) cells were generated by transfecting a 
mouse E-cadherin cDNA vector in SW480-ADH cells and selecting stable transfected cells 
with G418.25 Cells were maintained in DMEM and 10% FBS (both from Invitrogen) in 5% 
CO2 at 37°C. 
 
LEF1 and Fibronectin mRNA quantitation in SW480-ADH Mock, SnailOE and E-
cadherinOE cells 
 
RNA was extracted from cultured cells using the RNeasy Mini Kit (Qiagen). The level of 
LEF1 and Fibronectin/FN1 mRNA was measured by qRT-PCR in relation to the level of the 
18S rRNA using the comparative CT method. mRNA was retrotranscribed using the High-
Capacity cDNA Archive Kit (Applied Biosystems). The quantitative PCR reaction was 
performed in an ABI Prism 7900 HT thermal cycler using Power SYBR Green PCR Master 
Mix (both from Applied Biosystems). Thermal cycling consisted of a denaturing step at 95ºC 
for 10 min and 40 cycles of denaturing at 95ºC for 15 s and annealing and elongation at 60ºC 
for 60 s. Oligonucleotides used for LEF1 were 5’-CGAAGAGGAAGGCGATTTAG-3’ (sense) 
and 5’-GTCTGGCCACCTCGTGTC-3’ (antisense); whereas for Fibronectin/FN1 they were 
5’-GGGAGCCTCGAAGAGCAAG-3’ (sense) and 5’-AACCGGGCTTGCTTTGAC-3’ 
(antisense). 
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β-catenin and E-cadherin Immunofluorescence (IF) in SW480-ADH Mock, SnailOE and 
E-cadherinOE cells 
 
A total number of 50,000 cells were seeded into a Lab-TekII chamber slide/8 well on glass 
(LAB-TEK) for  48h. Cells were, then, fixed with cold methanol, washed twice with PBS and 
blocked for 1 hr in 1% BSA on PBS at room temperature. Afterwards, the cells were washed 
with PBS and incubated with β-catenin (BD Transduction, 1:100) or E-cadherin (BD 
Transduction, 1:50) antibodies for 1 hr. Then, we washed with PBS, and incubated with the 
secondary antibody conjugated with TRITC, (Jackson, 1:100) and Hoescht dye (50 ng/ml). 
Finally, cells were rinsed with PBS and coverslips were mounted using Fluoprep (BioMe- 
rieux). Samples were observed in a fluorescence microscope (Axiovert 200M, Zeiss) at 6303, 
using a rhodamine or DAPI filter. Images were obtained with a digital camera (Coolsnap, 
Photometrics) and MetaMorph 5.01 software. 
 
Reporter assays for β-catenin/TCF activity in SW480-ADH Mock, SnailOE and E-
cadherinOE cells 
 
Cells were transfected in triplicate 24-well dishes with 200 ng TOP-Flash or FOP-Flash 
plasmids and 20 ng pRLSV40 control plasmid (Promega) using jetPEI transfection reagent 
(PolyPlus Transfection). TOP-Flash and FOP-Flash plasmids contain multimerised wild-type 
(CCTTTGATC) or mutated (CCTTTGGCC) TCF/LEF1 binding sites upstream of a minimal c-
fos promoter driving luciferase gene expression (a gift from H. Clevers, Hubrecht Institute and 
University Medical Center, Utrecht, The Netherlands). Cells were harvested 48 h after 
transfection and Firefly luciferase (Luc) and Renilla reniformis luciferase (Rluc) activities were 
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measured separately using the Dual Luciferase Reporter Assay System (Promega) and a Lumat 
LB9507 luminometer (Berthold). Luc activity was normalised to Rluc activity. 
 
Experimental procedure and collection of human samples 
 
We injected 2x106 SW480-ADH Mock, Snail1OE or E-cadherinOE cells in the cecal wall of 
each Swiss nude mouse (Charles River), as described.19 Eight mice were included per group. 
Animals were kept until death or sacrificed at day 150. Mice were euthanized when they had 
lost 20% of  body weight or showed signs of pain, or if their tumors became too large. Local 
tumor and peritoneal tumor foci size was estimated as described.19 We obtained archived 
paraffin-embedded tissues from primary tumors and peritoneal metastases of 12 colorectal 
carcinoma patients treated at our hospital. 
 
Histopathological analysis 
 
We recorded colonic tumor growth and macroscopic tumor deposits at mouse necropsy. We 
calculated tumor take rate as the percentage of mice with local tumor growth. Samples were 
frozen in liquid nitrogen for molecular analysis or fixed in formalin and H&E stained.19 The 
extent of gland-like structures or necrosis, periodic acid shift (PAS) staining and Cytokeratin 
20 (CK20) and/or CDX2 immunostaining defined tumor differentiation.1 
 
Immunohistochemical (IHC) analysis 
 
Five µm sections of paraffin-embedded tumor tissues from the experimental and clinical 
studies were reacted with antibodies against β-catenin (Cell Signaling, 1:100), intracellular 
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domain of E-cadherin (BD Transduction, 1:200) and Snail1 (a gift from A. García de Herreros, 
IMIM-Hospital del Mar, Barcelona, Spain, 1:500), CK20 (DAKO, Ks 20.8 clone, 1:50) and 
CDX2 (88 clone, Biogenex, 1:50) according to standard procedures.26 The Snail1 antibody 
required target retrieval at pH 9.0 and sequential pre-treatment with 1% Triton (1 h), 0.1% 
BSA (1 h), and Fab fragment goat-antimouse IgG (1/50, 2 h; Jackson) before incubation. 
 
Western blotting analysis of stable cells and tumor xenografts 
 
LEF1 expression in cultured cells and E-cadherin and PS1 expression in mouse tumor samples 
were assessed by Western blotting (WB), as described.26 Antibody dilutions were: LEF1 (Cell 
Signaling, 1:1,000), E-cadherin (BD Transduction, 1:2,000), PS1 (Santa Cruz, 1:1,000), β-actin 
(Santa Cruz, 1:2,000), POD-conjugated goat anti-mouse, donkey anti-goat and goat anti-rabbit 
(Boehringer-Mannheim, 1:20,000). The anti-E-cadherin antibody detects the 120 kDa full-
length protein (FL), which remains in the cytosol or cell membrane, and also its 38 kDa 
proteolyzed cytosolic fragment (CF), which may translocate to the nucleus. The anti-PS1 
antibody detects the 50 kDa non-processed PS1 (npPS1) and the processed proteolytically 
active 29 kDa PS1 (pPS1). Supersignal chemoluminescence (Pierce) and Kodak 440 Digital 
Science Image sofware were used to measure band intensity in order to calculate the E-
cadherin proteolyzed ratio = CF/(CF + FL) after its normalization with endogenous β-actin. 
The same procedure was applied to calculate the PS1 proteolytic ratio = pS1/(npPS1 + pPS1). 
 
Quantitative PCR of PS1 in colorectal carcinoma samples 
 
We assessed PS1 expression in four 10 µm-thick sections of primary tumors and peritoneal 
carcinomatotic foci from two patients with colorectal signet-ring cell carcinoma (SRCC) that 
 10
showed different subcellular localization of E-cadherin. Before RNA extraction, the sections 
were deparaffined (xylol and ethanol 100%), centrifuged (10 min), incubated with 200 µl 
proteinase K lysis buffer (10 mM Tris/HCl EDTA, 2% SDS, 500 µg/ml proteinase K) for 2 h at 
56ºC. Five hundred µl of 100% ethanol was then added and the mixture was centrifuged at 
12,000 rpm for 15 min. RNA was extracted, tested for quality, retrotranscribed and quantified 
applying the comparative CT method, as described.27 We used pre-designed Taqman Gene 
Expression Primer and Probe Assays (Applied Biosystems) for PS1 (Hs00997789_m1), 
GAPDH (Hs99999905_m1), and β-actin (Hs99999903_m1). We also used a colorectal primary 
tumor as the calibration sample and the median of endogenous β-actin and GAPDH expression 
to normalize PCR results. 
 
Statistical Analysis 
 
All measured values were expressed as mean ± SE. ANOVA, Mann-Whitney or Student´s t 
tests were applied to assess the significance of the differences in mean final tumor volume, 
percentage of necrosis, rate of mitotis, rate of dead cell bodies, ratio of proteolyzed E-cadherin 
or ratio of proteolytic PS1. The Fisher´s exact test was used to evaluate the differences in take 
rate and lymph node or peritoneal tumor foci rates. The likelihood of mice survival was 
estimated according to Kaplan-Meier and survival distributions, whereas the comparison 
among the studied groups was performed applying the log-rank test. All tests were performed 
using SPSS version 11.0. Differences were considered significant at p < 0.05. 
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RESULTS 
 
Characterization of stable cell lines 
 
Mock, Snail1OE and E-cadherinOE SW480-ADH human colorectal carcinoma cells are depicted 
in Figure 1. Snail1OE cells displayed a mesenchymal phenotype and expressed high levels of 
the mesenchymal markers LEF1 and fibronectin (Figure 1B, D, E), whereas E-cadherinOE cells 
depicted an epithelial phenotype and reduced expression of the mesenchymal markers (Figure 
1C-E). Mock cells displayed an intermediate phenotype (Figure 1A, D, E). Moreover, β-
catenin/TCF transcriptional activity was strongly reduced in E-cadherinOE cells (Figure 1F), 
and accordingly β-catenin was absent in the nucleus (Figure 1G). In contrast, Mock or Snail1OE 
cells expressed nuclear β-catenin and displayed higher β-catenin/TCF transcriptional activity 
(Figure 1F, G). 
 
Differences in tumor take rate, colonization sites, and differentiation by Snail1 or E-
cadherin overexpression 
 
The study groups did not show significant differences in tumor take rate or in tumor spread to 
mesenteric lymph nodes (Table 1 and Supplemental figure S1C-E available at 
http://ajp.amjpathol.org).  Moreover, we did not observe macrometastases or micrometastases 
in liver or lung in any group. However, the peritoneal carcinomatotic rate was significantly 
different (p = 0.034) among groups (Table 1). The overexpression of Snail1, which decreases 
E-cadherin level  (Table 2), completely blocked peritoneal dissemination, since no mouse (0%) 
bearing a local tumor showed peritoneal foci in this group (Table 1). In contrast, E-cadherinOE 
cells generated peritoneal foci in all animals that developed local tumors (100%) (Table 1). 
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Mock cells displayed an intermediate E-cadherin expression level (Table 2) and yielded a 
moderate rate of peritoneal foci (40%) (Table 1). Therefore, E-cadherin expression appears to 
be required for the development of peritoneal foci. 
 
Consistent with the association described in vitro between Snail1 expression and the induction 
of mesenchymal characteristics and between E-cadherin expression and an epithelial 
phenotype, local tumors in the Snail1OE group were undifferentiated, PAS- and CK20-  (Figure 
2B, Table 2 and Supplemental figure S2B, E, H available at http://ajp.amjpathol.org), whereas 
tumors in the E-cadherinOE group were PAS+ and CK20+ (Supplemental figure S2C, F, I 
available at http://ajp.amjpathol.org) well-differentiated adenocarcinomas, containing glands 
and secretory mucini (Figure 2C and Table 2). Local tumors in the Mock group were poorly 
differentiated, PAS- and CK20- (Figure 2A, Table 2 and Supplemental figure S2A, D, G 
available at http://ajp.amjpathol.org). Lymph node tumor foci were PAS-, CK20- and poorly 
differentiated in the Mock group; they were PAS-, CK20- and undifferentiated in the Snail1OE 
group, and they were PAS+, CK20+ and well-differentiated in the E-cadherinOE group (Figure 
2D-F, Table 2 and Supplemental figure S3 available at http://ajp.amjpathol.org). Peritoneal 
tumors in the Mock group were PAS-, CK20- and poorly differentiated (Figure 3C, Table 2 and 
Supplemental figure S4A, C, E available at http://ajp.amjpathol.org), whereas foci in the E-
cadherinOE group were PAS+, CK20+ and well-differentiated (Figure 3D, Table 2 and 
Supplemental figure S4B, D, F available at http://ajp.amjpathol.org). In addition, all local 
tumors, lymph node foci and carcinomatotic foci were CDX2- in the three groups. Therefore, 
within each group local and secondary tumors showed the same degree of differentiation and 
marker expression.  
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Growth and expression of Snail1, E-cadherin and β-catenin in local tumors 
 
Tumors grew within the cecal wall and reached a macroscopic size in all groups (Supplemental 
figure S1A, B available at http://ajp.amjpathol.org). Those derived from Mock or E-cadherinOE 
cells were rounded, whereas tumors derived from Snail1OE cells were flattened and 
multilobular, and displayed less defined margins. Mean final tumor volume was non-
significantly (p = 0.063) higher in Snail1OE than in Mock or E-cadherinOE groups (Table 1). 
Local tumors in the Mock group displayed low nuclear Snail1 (Figure 4A), low membranous 
E-cadherin (Figure 5A) and high nuclear β-catenin (Figure 5D) expression (Table 2). Tumors 
derived from Snail1OE cells showed strong nuclear Snail1 (Figure 4B), undetectable E-cadherin 
(Figure 5C) and strong nuclear β-catenin (Figure 5E) expression (Table 2). Tumors derived 
from E-cadherinOE cells displayed undetectable Snail1 (Figure 4C), intense 
cytosolic/membranous E-cadherin (Figure 5C), and weak cytosolic β-catenin (Figure 5F) 
expression (Table 2). 
 
Therefore, we observed no association between Snail1, E-cadherin or β-catenin expression or 
their subcellular localization and local tumor growth. However, an association was found 
between membrane E-cadherin expression and tumor epithelial differentiation. Tumors of the 
Snail1OE group, which overexpressed  Snail1 (Figure 4B) and repressed E-cadherin (Figure 
5B), were undifferentiated (Figure 2B), whereas tumors expressing E-cadherin at the plasma 
membrane either at low (Mock group) or high (E-cadherinOE group) level (Figure 5A, C), 
showed epithelial differentiation (Figure 2A, C). 
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Growth and expression of Snail1, E-cadherin and β-catenin in lymph node tumor foci 
 
Whereas local tumors reached a similar size in all groups, lymph node tumor foci were 
significantly larger in Mock or E-cadherinOE than in the Snail1OE group (Supplemental figure 
S1C-E available at http://ajp.amjpathol.org). The number of lymph node foci per mouse was, 
however, slightly increased in the latter group (Table 1).  
 
Findings in local tumors and lymph node tumor foci were similar. Lymph node foci of mice 
bearing Mock cells showed weak nuclear Snail1 (Figure 4D), weak membranous E-cadherin 
(Figure 6A) and very strong and nuclear β-catenin (Figure 6D) expression (Table 2). Lymph 
node tumor foci in the Snail1OE group showed very intense and nuclear Snail1 (Figure 4E), 
undetectable E-cadherin (Figure 6B), and very intense and nuclear β-catenin (Figure 6E) 
expression (Table 2). Lymph node foci in the E-cadherinOE group showed undetectable Snail1 
(Figure 4F), moderate and membranous E-cadherin (Figure 6C) and cytosolic/membranous β-
catenin (Figure 6F) expression (Table 2). Therefore, there was no association between Snail1, 
E-cadherin or β-catenin expression or subcellular localization and foci growth. However, 
Snail1 overexpression and lack of E-cadherin were associated with undifferentiation (Figure 
4E, Table 2 and Supplemental figure S3B, E available at http://ajp.amjpathol.org), whereas 
membranous E-cadherin and lack of Snail1 were associated with differentiation (Figure 4F, 
Table 2 and Supplemental figure S3C, F available at http://ajp.amjpathol.org). 
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Growth and expression of Snail1, E-cadherin and β-catenin in peritoneal tumor foci 
 
Most peritoneal carcinomatotic foci generated in the Mock or E-cadherinOE groups reached a 
macroscopic size. Final foci size (3.6 ± 0.4 cm3, Figure 3B and Table 1) or mitotic rate (20.6 ± 
3.1, Figure 3D) in the E-cadherinOE group were significantly higher (p < 0.01) than in the 
Mock group (0.9 ± 0.5 cm3, Figure 3A and Table 1; and 12.1 ± 2.4, Figure 3C). The increase in 
peritoneal tumor foci growth killed all mice in the E-cadherinOE group, being their mean 
survival 67 ± 15 days (Figure 3E). In contrast, mice in the Snail1OE or Mock groups remained 
alive after 150 days, except for a mouse in the Snail1OE group that died of local tumor growth. 
Consistently, cumulative mouse survival was significantly higher (p = 0.01) in the Mock 
(100%, 5/5) or Snail1 (85%, 6/7) groups than in the E-cadherinOE (0%, 0/5) group (Figure 3E 
and Table 1). 
 
IHC analysis of peritoneal tumor foci in the Mock group showed weak and cytosolic Snail1, 
low and membranous E-cadherin, and very intense nuclear β-catenin expression (Figure 7A, C, 
E and Table 2). In contrast, E-cadherinOE peritoneal foci displayed undetectable Snail1, very 
intense and nuclear E-cadherin, and weak and cytosolic, but not nuclear β-catenin (Figure 7B, 
D, F and Table 2). Therefore, nuclear E-cadherin overexpression was associated with nuclear 
β-catenin withdrawal in peritoneal foci. In addition, the level of E-cadherin expression in 
peritoneal tumor foci correlated with growth rate and aggressiveness. 
 
We examined the relationship between E-cadherin proteolysis and nuclear translocation,28 and 
observed that the ratio of proteolyzed E-cadherin was significantly (p < 0.004) higher (10.2 ± 
1.2) in peritoneal foci in the E-cadherinOE  group than in the Mock group (3.7 ± 1.3) (Figure 
8A left, 8B and Supplemental table 1 available at http://ajp.amjpathol.org). This increased 
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proteolysis was associated with E-cadherin nuclear translocation and cytosolic β-catenin 
(Figure 7D, F and Table 2). In contrast, a low level of E-cadherin proteolysis in peritoneal foci 
of the Mock group (Figure 8A left, 8B and Supplemental table 1 available at 
http://ajp.amjpathol.org) was associated with nuclear β-catenin and lack of nuclear E-cadherin 
(Figure 7C, E and Table 2). Concordantly, E-cadherin was not proteolyzed in Mock or Snail1 
cultured cells, whereas E-cadherin fragments were detectable in E-cadherinOE cells (Figure 8A 
right). 
 
Tumor environment regulation of E-cadherin and PS1 in the mouse model 
 
We observed a differential regulation of expression, proteolysis and nuclear translocation of  E-
cadherin depending on tumor environment (Supplemental table 1 available at 
http://ajp.amjpathol.org). Thus, in the E-cadherinOE group, carcinomatotic foci showed 
significantly (p = 0.02) higher expression of E-cadherin (6.8 ± 0.7) than local tumors (1.8 ± 
0.4) (Supplemental table 1 available at http://ajp.amjpathol.org). Moreover, in these animals, 
the ratio of proteolyzed E-cadherin CF/(CF+FL) was significantly higher (p = 0.003) in 
peritoneal tumor foci (10.2 ± 1.2; Figure 8A left and 8C) than in local tumors (1.5 ± 1.2; Figure 
8A center and 8C) or cultured cells (0.9 ± 0.1; Figure 8A right and 8C). This increase in E-
cadherin expression and proteolysis in peritoneal foci of the E-cadherinOE group was associated 
with E-cadherin nuclear translocation (Figure 7D). E-cadherin was not detected in the nucleus 
of the corresponding local tumors (Figure 5C) or in the lymph node foci (Figure 6C). Neither 
did we find it in the nucleus of cultured E-cadherinOE cells (Figure 1H), where low levels of 
proteolyzed E-cadherin were detected (Supplemental table 1 available at 
http://ajp.amjpathol.org). 
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In addition, we studied PS1 expression in primary tumors and peritoneal foci in Mock and E-
cadherinOE groups (Figure 8D, E), since this γ-secretase component cleaves E-cadherin in 
SW480 cells.24 Total PS1 expression in carcinomatotic foci of the E-cadherinOE group (14.1 + 
7.3) was higher than in the Mock group (1.5 + 0.0) or than in E-cadherinOE cultured cells 
(Figure 8D and Supplemental table 1 available at http://ajp.amjpathol.org). Moreover, the 
expression of active, processed PS1 (pPS1) was significantly higher (p = 0.003) in peritoneal 
foci in the E-cadherinOE group (6.1 + 0.2) than in the Mock group (1.0 + 0.3) or in cultured 
cells (Figure 8D and E and Supplemental table 1 available at http://ajp.amjpathol.org). 
Therefore, the carcinomatotic foci derived from E-cadherinOE cells showed the highest levels 
of  total and proteolytically active PS1 and the highest level of proteolyzed E-cadherin (Figure 
8 and Supplemental table 1 available at http://ajp.amjpathol.org). Carcinomatotic foci derived 
from E-cadherinOE cells were also the only tumor tissues that expressed nuclear E-cadherin 
(Figure 7D and Table 2). 
 
Expression of E-cadherin and PS1 in colorectal cancer patients 
 
To assess the clinical relevance of our model, we studied E-cadherin and β-catenin expression 
in primary tumors and carcinomatotic foci of 12 colorectal cancer patients. We found 
membranous/cytosolic E-cadherin and nuclear β-catenin expression in all 12 primary colorectal 
carcinomas studied and in 11 out of the 12 carcinomatotic foci (data not shown). In contrast, 
one carcinomatotic foci from a colorectal signet-ring cell carcinoma (SRCC) patient presented 
nuclear E-cadherin (Figure 9C) and complete absence of β-catenin expression (Figure 9D). In 
this patient, both the primary colonic tumor and the peritoneal carcinomatotic foci displayed 
the nuclear shape, PAS positivity and cytosolic mucous deposits characteristic of signet-ring 
tumors (Supplemental figure S5 available at http://ajp.amjpathol.org). 
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We also studied PS1 expression in two SRCC patients showing differential subcellular 
distribution of E-cadherin. The primary tumor and carcinomatotic foci of one patient expressed 
moderate and membranous E-cadherin (Figure 9A), intense and mostly nuclear β-catenin 
(Figure 9B), and low PS1 RNA level (Figure 9E). The second SRCC patient showed the same 
pattern of E-cadherin and β-catenin expression in the primary tumor, but in contrast the 
carcinomatotic foci showed intense nuclear E-cadherin immunostaining (Figure 9C), complete 
absence of β-catenin expression (Figure 9D) and a thirteen-fold increase in PS1 RNA 
expression with respect to the primary tumor (Figure 9E). 
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DISCUSSION 
 
 
Unexpected tumor growth and dissemination induced by Snail1 or E-cadherin 
overexpression 
 
In our model, the degree of epithelial differentiation observed in tumor cells correlated better 
with their genotype than with tumor environment. Thus, cultured cells, local tumors, and 
lymph node and peritoneal tumor foci in each group showed similar differentiation patterns. As 
reported, Snail1 overexpression repressed E-cadherin and correlated with an undifferentiated 
phenotype, whereas membranous E-cadherin expression was associated with differentiation,29 
as assessed histologically, by PAS staining and CK20 immunostaining. 
 
Although an inverse correlation between Snail1 and E-cadherin expression was found in all 
tumor tissues, we did not observe the anticipated metastatic phenotypes. Thus, tumors 
overexpressing E-cadherin did not show reduced invasiveness, growth, or metastatic rate, and 
they were not associated with good prognosis, as it could be expected if it was acting as a 
tumor suppressor. Likewise and in contrast with reports in breast and other cancers, Snail1-
overexpressing tumors did not show increased invasiveness or metastatic rate, and they were 
not associated with poor prognosis.13-15 These results agree with previous observations that 
Snail1 expression in primary tumors does not have a prognostic value in sporadic colorectal 
cancer.16,17 Only the recent report by Francí et al (2009)18 has shown a correlation between 
Snail1 expression in the stroma of colon tumors and poor patient survival. The prognostic 
capacity of E-cadherin in colorectal cancer may require its analysis in both primary tumors and 
metastatic deposits. Thus, E-cadherin is often downregulated in primary tumors, while it is re-
expressed in metastases,7-10 frequently in the same patient.7,9 Moreover, whereas its 
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downregulation in the primary tumor associates with aggressiveness,7,8 high E-cadherin 
overexpression in liver or lymph node metastases associates with unfavourable outcome.8-10 
 
Our unexpected finding of a dramatic increase in peritoneal foci growth in mice injected with 
E-cadherinOE cells as compared to low E-cadherin-expressing Mock cells, and the lack of 
peritoneal foci development in mice injected with Snail1 overexpressing cells suggest the 
existence of mechanisms of tumorigenesis additional to the previously proposed for these 
proteins. The requirement of E-cadherin expression for peritoneal localization agrees with data 
in ovarian cancer30 and may preclude Snail1 cell colonization of this site. Alternatively, the 
growth of Snail1OE cells may be limited by the capacity of Snail1 to attenuate the cell cycle 
progression,12 which could explain the lack of peritoneal tumor foci or the reduced lymph node 
foci growth in this group. Therefore, although Snail1 may increase resistance to death, 
invasiveness, and dissemination,12 this effect may not directly translate into growth at the 
colonized site. 
 
E-cadherin gain of oncogenic function in peritoneal carcinomatotic foci 
 
Our observation of nuclear E-cadherin expression in E-cadherinOE carcinomatic foci has also 
been reported in a few human colorectal primary tumors and hepatic metastases, and it is 
highly prevalent in other tumors.31-34 Its functional implications, nevertheless, remain 
unexplored. We found nuclear β-catenin in local tumors and lymph node foci derived from 
Mock and Snail1OE cells, and in peritoneal tumor foci generated from Mock cells. However, 
we found E-cadherin rather than β-catenin in the nuclei of peritoneal foci derived from E-
cadherinOE cells. These foci showed aggressive growth, suggesting that nuclear E-cadherin 
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translocation may represent the gain of an oncogenic function. It is also consistent with the 
ability of nuclear E-cadherin to activate a non-canonical Wnt pathway.28 
The enhanced oncogenic function of E-cadherin observed in peritoneal foci derived from E-
cadherinOE cells may relate to the ability of the E-cadherin cytosolic tail to activate a 
transcription program other than the β-catenin-dependent Wnt pathway. This hypothesis agrees 
with the competition in vitro between E-cadherin cytosolic tail and Lef1 for binding to β-
catenin35 leading to the suppression of Lef1-mediated transactivation in SW480 cells.36  
 
Role of E-cadherin in colorectal cancer 
 
To date, the role of E-cadherin in colorectal cancer has not been completely dissected. We 
propose that E-cadherin may play a tumor suppressor role or an oncogenic role in colorectal 
tumorigenesis depending on its degree of proteolysis, which is determined by tumor 
environment. Its effect may depend on the relative abundance of full-length and proteolyzed E-
cadherin cytosolic species within the tumor cell.   
 
If full-length E-cadherin predominates, tumorigenesis will be inhibited by high intercellular 
adhesion that restricts invasion and migration. Consistently, its deletion or downregulation in 
animal models4 or in humans7  inhibits intercellular adhesion and promotes tumorigenesis by 
activating the Wnt/β-catenin and other signalling pathways.3,37 Accordingly, an association 
exists between increased membranous E-cadherin expression in human primary colorectal 
tumors and favorable outcome.8 
 
If cytosolic E-cadherin predominates over full-length E-cadherin, which would occur after E-
cadherin proteolysis, the cytosolic fragment would translocate to the nucleus and, if it is 
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accumulated at a sufficient amount, it may activate an oncogenic program. This is consistent 
with the previously reported induction of lymph node metastases by ectopic expression of E-
cadherin cytosolic fragment in a mouse model. The authors found that the overexpression of 
the cytosolic fragment induces subcellular redistribution and destabilization of endogenous 
full-length E-cadherin.4 It is also in agreement with the reported changes in the ratio of 
membranous and cytosolic E-cadherin depending on the metastatic site of colon tumors,8 with 
the observation of nuclear E-cadherin in a few colorectal primary tumors and hepatic 
metastases,31 and with the increased cytosolic E-cadherin expression found in metastases and 
its association with tumor recurrence in colorectal cancer patients.8  
 
In our model, the ratio between full-length and proteolyzed cytosolic E-cadherin changes with 
the environment. Thus, depending on the organ where the tumor grew the dramatic oncogenic 
effect was observed or not. This effect is probably related with the amount of active Presenilin1 
present in each environment and with the total expression of E-cadherin of the cells. Thus, 
primary tumors and lymph node metastases did not differ in number or size between Mock and 
E-cadherinOE groups because in both cases the level of cytosolic E-cadherin is low. In contrast, 
in E-cadherinOE carcinomatotic foci the levels of cytosolic E-cadherin predominates over full-
lengh E-cadherin, leading to E-cadherin nuclear translocation and to a dramatic increase in the 
size and number of metastatic foci. However, the amount of E-cadherin cytosolic fragment in 
Mock carcinomatotic foci is significantly lower than in those of E-cadherinOE group, and 
accordingly the size of peritoneal carcinomatosis in the Mock group was significantly reduced. 
 
To explain the uncommon association between the high growth rate and a well-differentiated 
phenotype38 occurring in peritoneal tumor foci derived from E-cadherinOE cells, we postulate 
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that membranous full-length E-cadherin promotes differentiation, while nuclear E-cadherin 
cytosolic tail stimulates tumor growth.  
 
On the other hand, the association between high levels of proteolytically active PS1, 
proteolyzed E-cadherin and nuclear E-cadherin in peritoneal foci of the E-cadherinOE group, as 
compared to peritoneal foci in the Mock group, identifies PS1 as a candidate protease for E-
cadherin cleavage, at least in our model. Remarkably, PS1 cleaves E-cadherin in different cell 
types,28,39 including SW480-ADH cells, and inhibits β-catenin/TCF transcriptional activity.24 
 
Environment-dependent regulation of tumor growth 
 
Several observations support an environment-dependent regulation of tumor cells in our 
system: 
1) The limited tumor foci growth observed in lymph node and peritoneal foci deriving from 
Snail1OE cells as compared with foci in Mock or E-cadherinOE group, while local tumor growth 
rate was similar in the three groups. 
2) The positive correlation between E-cadherin expression and foci growth in the peritoneum 
was not observed in the lymph node or colon microenvironment. 
3) E-cadherin proteolysis and nuclear translocation occurred exclusively in peritoneal foci but 
not in local tumors, lymph node foci, or cultured cells. 
 
We postulate that the peritoneal environment may trigger a gain of oncogenic function for E-
cadherin by enhancing both its expression and proteolysis in tumor cells. This would lead to an 
increased pool of cytosolic E-cadherin fragments, which may translocate to the nucleus, 
activate transcription and induce aggressive growth. Putatively, only tumor cells already 
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expressing a high level of E-cadherin (E-cadherinOE cells) would generate sufficient 
proteolyzed cytosolic species to cause detectable E-cadherin nuclear accumulation. The low E-
cadherin-expressing Mock foci may have not reached this threshold. 
 
Our proposal is consistent with γ-secretase cleavage of E-cadherin triggering E-cadherin 
nuclear translocation, in a similar manner to the regulated intramembranous proteolysis of type 
I transmembrane proteins.40 An oncogenic effect in colorectal carcinoma has also been recently 
demonstrated for EpCAM, another epithelial-specific cell adhesion molecule, through its 
overexpression, regulated intramembrane proteolysis and nuclear translocation.41,42 In addition, 
our proposal agrees with the tissue-specific pattern of metalloproteinases expression,43 and 
with the association of metalloproteinases with colorectal cancer prognosis.44 
 
Relevance of the model and clinical implications 
 
Our findings in colorectal cancer patients further support our proposal of an environment-
dependent oncogenic effect for E-cadherin, which could be mediated by the proteolytic activity 
of PS1. In the peritoneal metastases of a SRCC patient we found a remarkable increase in PS1 
mRNA levels, together with nuclear E-cadherin expression and absence of nuclear β-catenin. 
The patient’s primary tumor, however, displayed low PS1 mRNA levels and the expected 
pattern of nuclear β-catenin and cytosolic/membranous E-cadherin. The fact that SRCC is an 
aggressive metastatic tumor 45 is consistent with our observations in the mouse model. Our 
model allows the mechanistic dissection of peritoneal carcinomatosis in colorectal cancer in 
just three months. Unlike previous colorectal cancer models,46 it replicates the peritoneal 
carcinomatotic progression observed in clinical practice.47 This could be a good model for 
colorectal signet-ring cell carcinoma. In addition, our results support the need to  explore 
 25
whether or not the E-cadherin nuclear translocation observed in a small proportion of  hepatic 
metastases of sporadic colorectal carcinomas that overexpress E-cadherin31 associates with 
increased PS1 expression. 
In summary, we generated an animal model to study the role of Snail1 and E-cadherin in 
colorectal cancer metastagenesis. We observed an enhanced oncogenic effect in peritoneal foci 
which could be mediated through E-cadherin overexpression, coupled to its cleavage by PS1 
and the generation of E-cadherin cytosolic fragments. These fragments could translocate to the 
nucleus and activate a transcription program that may lead to aggressive growth and animal 
death. Our results suggest that E-cadherin overexpression may induce colorectal cancer 
metastases, at least in the peritoneal tissue, a function to be added to its known tumor-
suppressor or metastasis-suppressor role through the inhibition of invasion and epithelial-to-
mesenchymal transition.48 Our results also suggest that the design and use of new therapies 
directed to block PS1 expression or activity may improve prognosis and outcome in metastatic 
colorectal signet-ring cell cancer. 
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LEGENDS TO FIGURES 
 
Figure 1. Characterization of cultured human SW480-ADH colorectal cancer cells stably 
expressing an empty vector (Mock cells), or overexpressing Snail1 (Snail1OE cells) or E-
cadherin (E-cadherinOE). These cells were previously generated (see references 22 and 25). 
(A-C) Phase-contrast microscopy images of Mock (A), Snail1OE (B) and E-cadherinOE (C) 
SW480-ADH cells (Bar = 50 µm). Snail1OE cells displayed a large and stellate phenotype with 
few cell-cell contacts. E-cadherinOE cells displayed an epitheloid morphology, with higher cell 
density and cell-cell contacts. Mock cells displayed a mixed phenotype with an intermediate 
cell density and a few suspended cells. (D-E). The expression of the mesenchymal markers 
LEF1 and Fibronectin, as measured by WB (D) or qRT-PCR (E), was higher in Snail1OE than 
in Mock or E-cadherinOE cells. E-cadherinOE cells showed a complete shut-down of LEF1 
expression. (F) β-catenin/TCF transcriptional activity was extremely reduced in E-cadherinOE 
cells, as compared with Mock or Snail1OE cells. (G) β-catenin was nuclear (DAPI staining co-
localization) in Mock and Snail1OE cultured cells, whereas it was membranous and cytosolic in 
E-cadherinOE cells. (Bar = 50 µm) (H) E-cadherin was mostly membranous in E-cadherinOE 
cells. (Bar = 50 µm). 
 
Figure 2. Histopathology in local colonic tumors (A, B, C) and lymph node foci (D, E, F) 
derived from Mock (A, D), Snail1OE (B, E) and E-cadherinOE (C, F) cells. Local tumors 
were poorly-differentiated in the Mock group (A), undifferentiated in the Snail1OE group (B), 
and well-differentiated, containing glands and mucous deposits (black arrow) in the E-
cadherinOE group (C). The mitotic rate (white arrows) was similar in all three groups. All 
lymph node tumor foci (white asterisk) infiltrated the lymph nodes, pushing aside normal 
lymphocytes (white circle).  
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The lymph node tumor foci were poorly-differentiated in the Mock group (D), undifferentiated 
in the Snail1OE group (E) and showed differentiation features in E-cadherinOE group (F).  
 
Figure 3. Peritoneal carcinomatotic foci development and survival in mice implanted with 
Mock (A, C) or E-cadherinOE (B, D) cells. Tumor foci developed in the peritoneum (black 
arrow) after cecal implantation of Mock (A) or E-cadherinOE (B) cells, but not after 
implantation of Snail1OE cells. Tumor foci derived from E-cadherinOE cells were large (B) and 
well-differentiated and they had a high mitotic rate (D, black arrows). Tumor foci in the Mock 
group were small (A) and poorly-differentiated, and they had a lower mitotic rate (C, black 
arrows). (E) Cumulative survival was significantly higher in mice bearing tumors derived from 
Mock or from Snail1OE cells than in those bearing tumors derived from E-cadherinOE cells. 
 
Figure 4.  Snail1 expression in local colonic tumors (A, B, C) and lymph node foci (D, E, 
F) generated from Mock (A, D), Snail1OE (B, E) or E-cadherinOE (C, F) cells. Snail1 
immunostaining in both, local tumor and  lymph node foci were weak and nuclear in the Mock 
group (A, D), very strong and mostly nuclear in the Snail1OE group (B, E), and undetectable in 
the E-cadherin OE group (C, F). Black asterisk = tumor tissue; black circle = normal tissue.  
 
Figure 5. E-cadherin (A, B, C) and β-catenin (D, E, F) expression in local colonic tumors 
derived from Mock (A, D), Snail1OE (B, E) and E-cadherinOE (C, F) cells. E-cadherin 
immunostaining was weak and membranous in Mock group tumors (A), absent in Snail1OE 
group tumors (B) and intense, cytosolic and membranous in tumors derived from E-cadherinOE 
cells (C). β-catenin immunostaining was moderately intense and nuclear in Mock group tumors 
(D), very intense and mostly nuclear in Snail1OE group tumors (E), and weak and cytosolic in 
E-cadherinOE group tumors (F). Haematoxylin co-staining. 
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Figure 6. E-cadherin (A, B, C) and β-catenin (D, E, F) expression in lymph node foci 
derived from Mock (A, D), Snail1OE (B, E) or E-cadherinOE (C, F) cells. E-cadherin 
immunostaining was weak and membranous in foci of the Mock group (A), undetectable in the 
Snail1OE group (B), and cytosolic and membranous in the E-cadherinOE group (C). β-catenin 
immunostaining was very strong and mostly nuclear in foci of the Mock (D) or Snail1OE (E) 
groups, and weak, cytosolic and membranous in foci of the E-cadherinOE group (F). 
Haematoxylin co-staining. 
 
Figure 7. Snail1 (A, B), E-cadherin (C, D) and β-catenin (E, F) expression in peritoneal 
carcinomatotic foci of Mock (A, C, E) and E-cadherinOE (B, D, F) mice. Snail1 
immunostaining was weak and cytosolic in Mock (A) and undetectable in E-cadherinOE (B) 
foci. E-cadherin immunostaining in peritoneal foci was weak and membranous in the Mock 
group (C) but very intense and mostly nuclear in the E-cadherinOE group (D). β-catenin 
immunostaining in carcinomatotic foci was very strong and mostly nuclear in the Mock 
group(E), but weak and cytosolic in the E-cadherinOE group (F). Haematoxylin co-staining. 
White asterisk = tumor tissue. 
 
Figure 8. Increased level of proteolyzed E-cadherin and proteolytically active Presenilin1 
(PS1) in peritoneal carcinomatotic foci developed from E-cadherinOE cells. Peritoneal foci 
in the E-cadherinOE group overexpressed E-cadherin and showed a significantly (p < 0.005) 
higher level of proteolyzed E-cadherin than peritoneal foci in the Mock group (A left, B), than 
E-cadherinOE local colonic tumors (A center, C) or E-cadherinOE cultured cells (A right, C). 
Neither Mock nor Snail1 cultured cells showed E-cadherin proteolysis (A right). PS1 was 
barely detectable in Mock, Snail1OE and E-cadherinOE cells cultured in vitro (D). Moreover, 
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peritoneal foci generated from E-cadherinOE cells showed a significantly (p < 0.01) higher ratio 
of active PS1 than foci derived from Mock cells (D, E). Ratio of proteolyzed E-cadherin = 
CF/(FL + CF); CF = 38 kDa cytosolic E-cadherin fragment; FL = 120 kDa full-length E-
cadherin. Ratio of proteolytically active PS1 = pPS1/(npPS1 + pPS1); npPS1 = non-processed 
inactive 50 kDa PS1; pPS1 = processed and proteolytically active 29 kDa PS1; Control C1 = 
CHO k1 p70 cells; C2 = PC12 cells. 
 
Figure 9. Nuclear E-cadherin and Presenilin1 (PS1) expression in peritoneal foci of 
colorectal signet-ring cell carcinoma. Two patients were analysed. In the primary tumor and 
the carcinomatotic foci of one patient there were a moderate level of E-cadherin in the 
membrane (A), intense and mostly nuclear β-catenin expression (B), and low PS1 RNA level 
(E, qRT-PCR). In the second patient, we observed the same pattern of E-cadherin and β-
catenin expression in the primary tumor but, in contrast, the carcinomatotic foci showed 
intense nuclear E-cadherin immunostaining (C), complete absence of β-catenin expression (D) 
and a thirteen-fold increase in PS1 RNA expression (E). 
 
Table 1. Take rate and size of the local and secondary tumors developed after orthotopic implantation of three distinct 
human SW480-ADH-derived colorectal cancer cell lines in nude mice 
 
    Group 
 
 
Mice 
(n) 
 
Local Tumor 
 
  
  Secondary Tumor Foci 
                            
   
Take Rate 
(*) (%)  
 
Tumor volume 
(cm3) 
 
Lymph Node 
(**) (%) 
 
Peritoneum 
(**) (%) 
 
Peritoneal foci 
volume (cm3) 
 
Mock 
 
8 
 
5/8 (63) 
 
0.05 ± 0.02a 
 
2/5 (40) 
 
2/5 (40)b 
 
0.9 ± 0.5d 
 
Snail1OE 
 
8 
 
 
7/8 (88) 
 
0.13 ± 0.03a 
 
4/7 (47) 
 
0/7 (0)c 
 
--- 
 
E-cadherinOE 
 
8 
 
5/8 (63) 
 
0.08 ± 0.02a 
 
2/5 (40) 
 
5/5 (100)b, c 
 
3.6 ± 0.4d 
 
Mock group: mice implanted with Mock cells; Snail1OE group: mice implanted with Snail1 overexpressing cells; E-cadherin OE group: mice 
implanted with E-cadherin overexpressing cells. 
(*) Mice with local tumors/total number of injected mice per group; (**) Mice with tumor foci at the particular site/total number of mice bearing local 
tumors. 
---: Undetectable; a Non-significant differences (p = 0.063); Significant differences at p = 0.042b or p = 0.008c (Fisher test); d Significant differences at 
p = 0.034 (Student t-test). 
 
Table 2. Histopathology and CK20, Snail1, E-cadherin and β-catenin expression and subcellular 
localization in local tumors and secondary tumor foci generated from the three types of implanted 
SW480-ADH cells 
 
Group 
 
Local Tumorb 
 
  
Degree of 
Differentiation 
 
PAS 
staining 
 
   CK20 
 
Snail1a 
 
E-cadherina 
 
 
β-catenina 
 
 
Mock 
 
Poorly 
differentiated 
 
_ 
 
_ 
 
+/- 
Nuc./Cyt. 
 
+/-  
Cyt./Mb. 
 
++ 
Nuc. 
 
Snail1OE 
 
Undifferentiated 
 
 
_ 
 
_ 
 
+++ 
Nuc./Cyt. 
 
--- 
 
+++ 
Nuc./Cyt. 
 
E-cadherinOE 
 
Well-
differentiated 
 
+ 
 
+++ 
Cyt. 
 
--- 
 
++ 
Cyt./Mb. 
 
+/- 
Cyt. 
 
 
 Group 
 
Lymph Node Secondary Tumor focic 
 
  
Degree of 
Differentiation 
 
PAS 
staining 
 
CK20 
 
Snail1 
 
E-cadherin 
 
 
β-catenin 
 
 
Mock 
 
Poorly 
differentiated 
 
_ 
 
       _ 
 
+/- 
Nuc./Cyt. 
 
+/- 
Mb. 
 
+++ 
Nuc./Cyt. 
 
Snail1OE 
 
Undifferentiated 
 
 
_ 
 
       _ 
 
+++ 
Nuc./Cyt. 
 
--- 
 
+++ 
Nuc./Cyt. 
 
E-cadherinOE 
 
Well-
differentiated 
 
+ 
 
+++ 
Cyt. 
 
--- 
 
+ 
Cyt./Mb. 
 
+/- 
Cyt./Mb. 
 
 
Group  
 
Secondary Peritoneal Carcinomatotic Focid 
 
  
Degree of 
Differentiation 
 
PAS 
staining 
 
CK20 
 
Snail1 
 
E-cadherin  
 
β-catenin 
 
 
Mock 
 
Poorly 
differentiated 
 
_ 
 
_ 
 
+/- 
Cyt. 
 
+  
Mb. 
 
    +++ 
         
Nuc./Cyt. 
 
 
E-cadherinOE 
 
Well-
differentiated 
 
+ 
 
+++ 
Cyt. 
 
--- 
 
+++ 
Nuc./Cyt./Mb. 
 
+/- 
         Cyt. 
 
Mock group: mice implanted with Mock cells; Snail1OE group: mice implanted with Snail1 overexpressing cells; E-
cadherinOE group: mice implanted with E-cadherin overexpressing cells. 
 40
a Nuc.: nuclear staining, Cyt.: cytoplasmic staining, Mb.: membranous staining, --- :undetectable; b See Figure 2, Figure 4, 
Figure 5 and Supplemental  figure S2). c See Figure 2, Figure 4,  Figure 6 and Supplemental figure S3); d See Figure 3, 
Figure 7 and Supplemental  figure S4. (Supplemental  figures are available at http://ajp.amjpathol.org). 
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Supplemental figure S1. Local colonic tumors and lymphatic tumor foci 
development after orthotopic cell microinjection (OCMI) in nude mice. Local 
tumors in mice implanted with Mock, Snail1OE or E-cadherinOE cells grew within the 
cecal wall (A) and protruded towards the lumen (B), reaching a macroscopic size in all 
groups. They were rounded in the Mock or E-cadherinOE group, whereas tumors derived 
from Snail1OE cells were flattened and multilobular and displayed less defined margins. 
The mean final tumor volume was higher, although non-significantly (p = 0.063), in the 
Snail1OE group than in Mock or E-cadherinOE groups (see Table 1). Tumor foci (white 
arrows) developed in the mesenteric lymph nodes were significantly (p = 0.042) larger 
in Mock (C) or E-cadherinOE groups (E) than in the Snail1OE group (D). (B, Bar = 1 
cm). 
Supplemental figure S2. Hematoxylin-eosin (A, B, C), PAS (D, E, F) and CK20 (G, 
H, I) staining of OCMI-derived local colonic tumors in nude mice. All tumors 
(white asterisks) infiltrated the normal colonic mucosa (black asterisks). Tumors in the 
E-cadherinOE group were well-differentiated (C), PAS+ (F) and CK20+ (I), whereas they 
were PAS- (E), CK20- (H) and poorly-differentiated (B) in the Snail1OE group or 
undifferentiated (A), PAS- (D) and CK20- (G) in the Mock group. Normal colonic 
mucosa stained for PAS (E, black asterisk) and CK20 (G, H, black asterisk). The 
number of mitotic figures and cell death bodies were similar in tumors of the three 
groups.  
 
Supplemental figure S3. PAS (A, B, C) and CK20 (D, E, F) staining of OCMI-
derived mesenteric lymph node tumors in nude mice. All tumors (black asterisks) 
infiltrated the mesenteric lymph nodes (black circles). Tumors in the E-cadherinOE 
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group were PAS+ (C, black arrows) and CK20+ (F), whereas they were PAS- (B) and 
CK20- (E) in the Snail1OE group, and PAS- (A) and CK20- (D) in the Mock group.  
 
Supplemental figure S4. Histopathology of peritoneal carcinomatotic foci 
developed from orthotopic microinjection of Mock (A, C, E) or E-cadherinOE (B, 
D, F) cells. Carcinomatotic foci (white asterisks) in the Mock group were poorly-
differentiated (A), PAS- (C) and CK20- (E), whereas in the E-cadherinOE group tumors 
were well-differentiated (B), PAS+ (D) and CK20+ (F). Tumor foci from both groups 
invaded the peritoneum (A and B, black asterisks). Mitotic rate in peritoneal foci of the 
E-cadherinOE group (20.6 ± 3.1) was significantly higher (p < 0.01) than in the Mock 
group (12.1 ± 2.4). E-cadherinOE and Mock peritoneal tumor foci did not differ in 
percent of necrosis (39.3 ± 2.2 vs 42.4 ± 5.1, p = 0.58) or dead cell body rate (5.2 ± 0.9 
vs 7.9 ± 1.3, p = 0.14). 
 
Supplemental figure S5. Histopathology of a representative human colorectal 
signet-ring cell carcinoma. After H&E (A, D) and PAS (B, C, E, F) staining both the 
primary colonic tumor (A, B, C) and the peritoneal carcinomatotic foci (D, E, F) 
displayed the nuclear shape, PAS positivity and cytosolic mucous deposits characteristic 
of this tumor type. 





Supplemental Table 1. Environment-dependent regulation of E-cadherin and Presenilin1 (PS1) 
at the different tumor sites in the mouse model and in vitro 
   
Group  *Total (CF + FL) E-cadherin Expression Ratio 
(tumor site/local tumor) 
      
  Local tumor  Peritoneal 
carcinomatotic foci 
Cell culture 
      
Mock  1.0 ± 0.1a  4.2 ± 0.1a --- 
      
E-cadherinOE  1.8 ± 0.4b, c  6.8 ± 0.7b 7.8 ± 1.0c 
      
  **Ratio of Proteolyzed (CF/(CF + FL) E-cadherin 
(tumor site/local tumor) 
      
  Local tumor  Peritoneal 
carcinomatotic foci 
Cell culture 
      
Mock  1.0 ± 0.4  3.7 ± 1.3d --- 
      
E-cadherinOE  1.5 ± 1.2e  10.2 ± 1.2d, e, f 0.9 ± 0.1f 
      
  # Total (pPS1 + npPS1) Presenilin1 Expression Ratio 
(tumor site/Mock cells) 
      
  Local tumor  Peritoneal 
carcinomatotic foci 
Cell culture 
      
Mock  N.D  1.5 ± 0.1 N.S. 1.0 ± 0.2 
      
E-cadherinOE  N.D  14.1 ± 7.3 N.S. 0.9 ± 0.1 
      
  ## Presenilin1 Proteolytic (pPS1/(pPS1 + npPS1) Ratio 
(tumor site/Mock cells) 
      
  Local tumor  Peritoneal 
carcinomatotic foci 
Cell culture 
      
Mock  N.D  1.0 ± 0.3g 1.0 ± 0.1 
      
E-cadherinOE  N.D  6.1 ± 0.2g, h 1.8 ± 0.9h 
      
 
Mock group: mice implanted with Mock cells 
E-cadherinOE group: mice implanted with E-cadherin overexpressing cells 
(*) Mean ± SE of the ratio between total E-cadherin expression at each particular site and that found in local tumor from Mock 
cells (see Figure 8A) 
(**) Mean ± SE of the ratio between proteolyzed E-cadherin expression at each particular site and that found in local tumor from 
Mock cells (see Figure 8A-C) 
(#) Mean ± SE of the ratio between total PS1 expression at each particular site and that found in cultured Mock cells (see Figure 
8D) 
(##) Mean ± SE of the ratio between proteolyzed PS1 expression at each particular site and that found in cultured Mock cells (see 
Figure 8D, E) 
Significant differences at p = 0.008a; p = 0.002b; p = 0.009c; p = 0.004d; p = 0.0002e; p = 0.0003f; p = 0.003g; p = 0.018h; N.S.: 
non-significant differences (Student t-test) 
CF: cytosolic E-cadherin fragment; FL: full-length E-cadherin 
pPS1: processed proteolytically active PS1; npPS1: non-processed proteolytically inactive PS1 
---: undetectable; N.D: not done 
